BTIG analyst Thomas Shrader lowered the firm’s price target on Acumen (ABOS) to $4 from $11 and keeps a Buy rating on the shares. In a broader research note previewing Q3 results for select biotech names, the firm is updating its assumptions and models for the company, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS: